Merck and Simcere Initiate Joint Venture

Merck and Simcere Pharmaceutical announced on September 19 the official start of their JV operations. The deal was signed in July 2011 to form a JV (Merck 51%, Simcere49%) which will incorporate the technologies and resources of Merck and local company Simcere to target both the urban and rural mark...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Singapore commences Phase 2 of its National Precision Medicine program

News Commentary | April 08, 2021

Singapore's National Precision Medicine (NPM) program is a 10‑year plan aimed at transforming the Singaporean healthcare system by understanding how genomic, phenotypic, lifestyle, and clinical factors contribute to the health of Singaporeans. NPM Phase I began in 2017 and resulted in a databank ... To read more, click here.

BioNTech to set up its regional headquarters and an mRNA vaccine manufacturing facility in Singapore

News Commentary | May 12, 2021

Pfizer's biotech partner that developed the mRNA vaccine against COVID‑19 has moved quickly to ensure it can be elastic in its response to shifting regional and global supply needs for its vaccine given the unpredictable outbreaks in recent times. This move also comes just weeks after Sanofi ... To read more, click here.

South Korea to invest almost $1 billion to build national digital library of healthcare data by 2028

News Commentary | September 20, 2021

South Korea joins a growing club of countries focusing on national‑level precision medicine projects to combat rising healthcare costs. Like Singapore, it has managed to get buy‑in from a multiministerial taskforce to greenlight this project. It will invest almost $1 billion from 2023 to 2028 to ... Not part of subscription